A senescent-immune reserve niche model for incomplete lobular involution in the aging breast

TL;DR

This paper proposes a new model where persistent lobules in the aging breast are maintained by an active senescent-immune niche, influencing breast cancer risk and highlighting the importance of immune surveillance during menopause.

Contribution

It introduces a novel framework integrating biology and epidemiology to explain incomplete lobular involution as an active process involving immune and senescent cell interactions.

Findings

Persistent lobules are maintained by an active reserve niche.

Impaired immune surveillance may lead to a self-sustaining senescent-immune niche.

The perimenopausal window is critical for risk stratification and prevention.

Abstract

Breast cancer incidence rises with age and peaks across the menopausal transition, yet why some postmenopausal lobules persist, and why that persistence predicts cancer risk, remains unresolved. Incomplete age-related lobular involution is one of the strongest tissue-level predictors of subsequent breast cancer, but it is still commonly viewed as passive failure of hormonally driven regression. This Review proposes a different framework: persistent lobules are maintained by an active reserve niche that outlasts its reproductive function. By integrating breast epidemiology, mammary stromal biology, cellular senescence, immune surveillance, and comparative reserve systems in skeletal muscle, hematopoiesis, and postmenopausal endometrium, we argue that menopause is a biological control point at which tissue fate diverges. Efficient clearance of senescent cells permits lobular regression to complete, whereas impaired immune surveillance may allow inflammatory paracrine signaling, macrophage reprogramming, and immune evasion to create a self-sustaining senescent-immune niche lock. This framework explains why persistent lobules are biologically active, shifts attention from epithelial quantity to microenvironmental state, and identifies the perimenopausal window as a promising interval for biomarker-guided risk stratification and prevention.